Does Rallies show Form 4 insider transactions for ERAS?

Yes. Rallies tracks ERAS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ERAS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ERAS. It does not provide personalized investment advice.

ERAS (Erasca, Inc. Common Stock) Stock Analysis - Insider Trades

Erasca, Inc. Common Stock (ERAS) is a publicly traded Healthcare sector company. As of May 21, 2026, ERAS trades at $11.12 with a market cap of $3.19B and a P/E ratio of -25.11. ERAS moved +7.95% today. Year to date, ERAS is +218.63%; over the trailing twelve months it is +768.75%. Its 52-week range spans $1.01 to $24.28. Analyst consensus is buy with an average price target of $20.27. Rallies surfaces ERAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ERAS stock inside the company?

Recent ERAS insider activity includes Garner Ebun sold 80.00K, Morris Shannon sold 20.00K, Garner Ebun sold 120.00K, and Casdin Alexander W. bought 80.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ERAS Key Metrics

Key financial metrics for ERAS
Metric	Value
Price	$11.12
Market Cap	$3.19B
P/E Ratio	-25.11
EPS	$-0.44
Dividend Yield	0.00%
52-Week High	$24.28
52-Week Low	$1.01
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-124.55M
Gross Margin	0.00%

Recent ERAS Insider Trades

Garner Ebun sold 80.00K (~$1.31M) on Apr 1, 2026.
Morris Shannon sold 20.00K (~$300.76K) on Mar 4, 2026.
Garner Ebun sold 120.00K (~$670.81K) on Jan 7, 2026.
Casdin Alexander W. bought 80.00K (~$181.92K) on May 21, 2024.

Latest ERAS News

Erasca Bolsters Cash to $408.5M, Highlights ERAS-0015 NSCLC and PDAC Responses — May 11, 2026
Erasca Strikes Merck Pact to Combine ERAS-0015 with Keytruda in Phase 1 Trial — May 11, 2026
Erasca slides 5% after ERAS-0015 update pushes key readouts into 2027 — Apr 29, 2026
Erasca Shares Plunge 46% After Trial Death Despite 62% NSCLC Response — Apr 29, 2026
Erasca plunges 43% after ERAS-0015 trial patient death sparks safety fears — Apr 28, 2026

ERAS Analyst Consensus

11 analysts cover ERAS: 0 strong buy, 9 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.27.

Common questions about ERAS

Who is trading ERAS stock inside the company?: Recent ERAS insider activity includes Garner Ebun sold 80.00K, Morris Shannon sold 20.00K, Garner Ebun sold 120.00K, and Casdin Alexander W. bought 80.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ERAS?: Yes. Rallies tracks ERAS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ERAS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ERAS. It does not provide personalized investment advice.